LPRS2
MCID: LPR022
MIFTS: 37

Leprosy 2 (LPRS2)

Categories: Eye diseases, Genetic diseases, Immune diseases, Infectious diseases, Neuronal diseases, Rare diseases, Reproductive diseases, Respiratory diseases, Skin diseases

Aliases & Classifications for Leprosy 2

MalaCards integrated aliases for Leprosy 2:

Name: Leprosy 2 56 29 6
Leprosy, Susceptibility to, 2 56 71
Leprosy, Type 2 39
Leprosy 71
Lprs2 56

Classifications:



External Ids:

OMIM 56 607572
UMLS 71 C0023343 C1843632

Summaries for Leprosy 2

MalaCards based summary : Leprosy 2, also known as leprosy, susceptibility to, 2, is related to leprosy 3 and hansen's disease. An important gene associated with Leprosy 2 is PRKN (Parkin RBR E3 Ubiquitin Protein Ligase), and among its related pathways/superpathways are cAMP signaling pathway and Neuroscience. The drugs Vitamins and Antibiotics, Antitubercular have been mentioned in the context of this disorder. Affiliated tissues include testes, skin and prostate.

More information from OMIM: 607572

Related Diseases for Leprosy 2

Diseases in the Leprosy 3 family:

Leprosy 2 Leprosy 1
Leprosy 4 Leprosy 5
Leprosy 6

Diseases related to Leprosy 2 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 51)
# Related Disease Score Top Affiliating Genes
1 leprosy 3 10.4
2 hansen's disease 10.4
3 lepromatous leprosy 10.0
4 pancreatic somatostatinoma 9.9 VIP CALCA
5 somatostatinoma 9.9 VIP CALCA
6 pancreatic cholera 9.9 VIP CALCA
7 endocrine pancreas disease 9.9 VIP CALCA
8 cluster headache 9.9 VIP CALCA
9 colon neuroendocrine neoplasm 9.9 VIP CALCA
10 autonomic nervous system benign neoplasm 9.9 VIP CALCA
11 peripheral nervous system benign neoplasm 9.9 VIP CALCA
12 vipoma 9.9 VIP CALCA
13 tuberculoid leprosy 9.9
14 islet cell tumor 9.8 VIP CALCA
15 ileus 9.8 VIP CALCA
16 borderline leprosy 9.8
17 neutropenia 9.8
18 chromoblastomycosis 9.8
19 mucormycosis 9.8
20 rhinitis 9.8 VIP NPY
21 small cell cancer of the lung 9.8 VIP CALCA
22 bronchitis 9.8 VIP CALCA
23 migraine with aura 9.7 VIP CALCA
24 ganglioneuroblastoma 9.7 VIP NPY
25 neuroendocrine tumor 9.7 VIP CALCA
26 kala-azar 1 9.7
27 leishmaniasis 9.7
28 pelvic organ prolapse 9.7 VIP NPY
29 perianal hematoma 9.7 NPY CALCA
30 carcinoid syndrome 9.7 NPY CALCA
31 achalasia 9.7 VIP NPY
32 reflex sympathetic dystrophy 9.7 NPY CALCA
33 normal pressure hydrocephalus 9.7 VIP NPY
34 rabies 9.7 VIP NPY
35 autonomic nervous system disease 9.7 NPY CALCA
36 machado-joseph disease 9.6 PRKN NPY
37 complex regional pain syndrome 9.6 NPY CALCA
38 degenerative disc disease 9.6 NPY CALCA
39 fibromyalgia 9.6 NPY CALCA
40 gastroesophageal reflux 9.5 VIP NPY
41 peripheral nervous system disease 9.4 PRKN CALCA
42 holoprosencephaly 9.4 VIP NPY
43 hydrocephalus 9.4 VIP PRKN NPY
44 neuroblastoma 9.3 VIP PRKN NPY
45 vasomotor rhinitis 9.3 VIP NPY CALCA
46 constipation 9.3 VIP NPY CALCA
47 hirschsprung disease 1 9.3 VIP NPY CALCA
48 migraine with or without aura 1 9.3 VIP NPY CALCA
49 pheochromocytoma 9.3 VIP NPY CALCA
50 hypertension, essential 9.0 VIP NPY CALCA

Graphical network of the top 20 diseases related to Leprosy 2:



Diseases related to Leprosy 2

Symptoms & Phenotypes for Leprosy 2

Clinical features from OMIM:

607572

Drugs & Therapeutics for Leprosy 2

Drugs for Leprosy 2 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 122)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Vitamins Phase 4
2 Antibiotics, Antitubercular Phase 4
3 Antiprotozoal Agents Phase 4
4 Antiparasitic Agents Phase 4
5 Antimalarials Phase 4
6 Anti-Bacterial Agents Phase 4
7 Anti-Infective Agents Phase 4
8 Immunologic Factors Phase 4
9 Immunosuppressive Agents Phase 4
10 Angiogenesis Inhibitors Phase 4
11
Amitriptyline Approved Phase 3 50-48-6 2160
12
Tramadol Approved, Investigational Phase 3 27203-92-5 33741
13
Perphenazine Approved Phase 3 58-39-9 4748
14
Minocycline Approved, Investigational Phase 3 10118-90-8 5281021
15
Clotrimazole Approved, Vet_approved Phase 2, Phase 3 23593-75-1 2812
16
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3 22916-47-8 4189
17
Rifampicin Approved Phase 2, Phase 3 13292-46-1 5381226 5458213
18
Clarithromycin Approved Phase 2, Phase 3 81103-11-9 84029
19
Streptomycin Approved, Vet_approved Phase 2, Phase 3 57-92-1 19649
20
Leuprolide Approved, Investigational Phase 3 53714-56-0 657181 3911
21
Goserelin Approved Phase 3 65807-02-5 5311128 47725
22
Miltefosine Approved, Investigational Phase 3 58066-85-6 3600
23
Tocopherol Approved, Investigational Phase 3 1406-66-2, 54-28-4 14986
24
Infliximab Approved Phase 3 170277-31-3
25
Clofazimine Approved, Investigational Phase 2, Phase 3 2030-63-9 2794
26
Bedaquiline Approved Phase 2, Phase 3 843663-66-1
27
Linezolid Approved, Investigational Phase 2, Phase 3 165800-03-3 441401
28
Moxifloxacin Approved, Investigational Phase 2, Phase 3 354812-41-2, 151096-09-2 152946
29
Vitamin E Approved, Nutraceutical, Vet_approved Phase 3 59-02-9 14985
30 Tocotrienol Investigational Phase 3 6829-55-6
31 Antidepressive Agents Phase 3
32 Narcotics Phase 3
33 Analgesics, Non-Narcotic Phase 3
34 Adrenergic Agents Phase 3
35 Analgesics Phase 3
36 Psychotropic Drugs Phase 3
37 Analgesics, Opioid Phase 3
38 Antipsychotic Agents Phase 3
39 Amitriptyline, perphenazine drug combination Phase 3
40 Antidepressive Agents, Tricyclic Phase 3
41 Hormones Phase 3
42 Antineoplastic Agents, Hormonal Phase 3
43 Cyclosporins Phase 2, Phase 3
44 Antifungal Agents Phase 2, Phase 3
45 Calcineurin Inhibitors Phase 2, Phase 3
46 Adjuvants, Immunologic Phase 3
47 Cytochrome P-450 Enzyme Inhibitors Phase 2, Phase 3
48 Cytochrome P-450 CYP3A Inhibitors Phase 2, Phase 3
49 Androgens Phase 3
50 Tocotrienols Phase 3

Interventional clinical trials:

(show top 50) (show all 69)
# Name Status NCT ID Phase Drugs
1 A Phase IV, Randomised, Multicentre, Double-blind, Study to Evaluate the Clinical Utility of Prospective Genetic Screening (HLA-B*1301) for Susceptibility to Dapsone Hypersensitivity Syndrome Unknown status NCT02550080 Phase 4 Dapsone
2 Evaluating Immunogenicity and Safety Effect on Combined Immune Effect of EV71 Inactivated Vaccine and HepB、MPSV-A、MR、JE-L:A Multi-center Randomized Controlled Trial Unknown status NCT03519568 Phase 4
3 Effect of Additional Clofazimine on ENL Reactions in Leprosy Completed NCT01290744 Phase 4 Clofazimine;Placebo
4 Population Pharmacokinetic Analysis of Dapsone in Normal, Overweight and Obese Volunteers Completed NCT01165840 Phase 4 Dapsone
5 Independent Study to Establish the Efficacy of the Six Doses Uniform MDT Regimen (U-MDT) for Leprosy Patients Completed NCT00669643 Phase 4 PB 6 doses - Rifampicin and Dapsone;PB 6 doses - Rifampicin, Clofazimine and Dapsone;MB 12 doses - Rifampicin, Clofazimine and Dapsone;MB 6 doses - Rifampicin, Clofazimine and Dapsone
6 Use of Thalidomide in Chronic Uveitis Terminated NCT00314665 Phase 4 Thalidomide
7 Treatment of Neuropathic Pain in Leprosy: a Randomized Double Blind Controlled Study Unknown status NCT03324035 Phase 3 Amitriptyline;Placebo oral capsule;Tramadol
8 Minocycline Treatment in Patients With Idiopathic Pulmonary Fibrosis Being Treated With Standard of Care Therapy- a Pilot Study Unknown status NCT00203697 Phase 3 minocycline
9 A Randomised Double Blind Controlled Trial Comparing Ciclosporin and Prednisolone in the Treatment of New Leprosy Type 1 Reactions Completed NCT00919815 Phase 2, Phase 3 Ciclosporin;Prednisolone
10 Efficacy and Safety of Immunomodulator (Mycobacterium w.) as an Adjunct Therapy in Category I Pulmonary Tuberculosis and Along With Assessment of Immunological Parameters Completed NCT00341328 Phase 3
11 Efficacy and Safety Study of Immunomodulator (Mycobacterium w) as an Adjunct Therapy in Category-II Pulmonary Tuberculosis Along With Assessment of Immunological Parameters Completed NCT00265226 Phase 3
12 Randomized Controlled Trial Comparing Efficacy of 8 Weeks Treatment With Clarithromycin and Rifampicin Versus Streptomycin and Rifampicin for Buruli Ulcer (M. Ulcerans Infection) Completed NCT01659437 Phase 2, Phase 3 Clarithromycin Extended Release;Streptomycin intramuscular injection
13 A Double Blinded Randomized Crossover Phase III Study of Oral Thalidomide Versus Placebo in Patients With Stage D0 Androgen Dependent Prostate Cancer Following Limited Hormonal Ablation Completed NCT00004635 Phase 3 Thalidomide;leuprolide acetate;goserelin
14 A Study for Safety and Efficacy of Miltefosine for Treatment of Children and Adolescents With Post-Kala-azar Dermal Leishmaniasis (PKDL) in Bangladesh and Association of Serum Vitamin E and Exposure to Arsenic With PKDL Completed NCT02193022 Phase 3 Miltefosine
15 Phase 2 Study for Infrared Thermometry Used by Diabetic Patients at Home Completed NCT00289497 Phase 2, Phase 3
16 Post ExpOsure Prophylaxis for LEprosy in the Comoros and Madagascar Recruiting NCT03662022 Phase 3 Rifampicin
17 Efficacy and Safety of Low Dose Thalidomide in Transfusion Dependent Thalassemia Patients of Pakistan Recruiting NCT03651102 Phase 2, Phase 3 Thalidomide Oral Product
18 Thalidomide, a Novel Immunological Treatment to Modify the Natural History of Paediatric Crohn's Disease: a New Proposal From a Well-established Paediatric Research Network Recruiting NCT03221166 Phase 3 Thalidomide;Infliximab
19 Patient-reported Experiences and Quality of Life Outcomes in the TB-PRACTECAL Clinical Trial Not yet recruiting NCT03942354 Phase 2, Phase 3 Bedaquiline;Pretomanid;Moxifloxacin;Linezolid;Clofazimine;Directly observed therapy (DOT)
20 Economic Evaluation of New MDR TB Regimens (PRACTECAL EE) Not yet recruiting NCT04207112 Phase 2, Phase 3 Bedaquiline;Pretomanid;Moxifloxacin;Linezolid;Clofazimine;Standard Drugs
21 Pharmacokinetics and Pharmacodynamics Sub-study for TB-PRACTECAL Clinical Trial ( PRACTECAL-PKPD) Not yet recruiting NCT04081077 Phase 2, Phase 3 Bedaquiline;Pretomanid;Moxifloxacin;Linezolid;Clofazimine
22 To Study the Efficacy of Teriparatide in Improving Remodeling of Foot Bones in Chronic Charcot Neuroarthropathy in Patients With Diabetes Mellitus. Unknown status NCT02023411 Phase 2 Teriparatide
23 Phase 2 Randomized, Multicenter, Safety and Efficacy Trial to Evaluate Different Oral Benznidazole Monotherapy and Benznidazole/E1224 Combination Regimens for the Treatment of Adult Patients With Chronic Indeterminate Chagas Disease Unknown status NCT03378661 Phase 2 Benznidazole;E1224;E1224 Placebo;Benznidazole Placebo
24 Two New Leprosy Skin Test Antigens: MLSA-LAM and MLCwA Phase II Study in a Leprosy-Endemic Region Completed NCT00128193 Phase 2
25 A Pilot Study Assessing the Efficacy and Safety of Ciclosporin as a Second -Line Drug in Patients With Type 1 Reactions Who Have Not Responded to a 12 Week Course of Prednisolone. Completed NCT00919451 Phase 2 ciclosporin
26 A Pilot (Double Blind Controlled) Study Randomizing Patients With New Acute ENL to Treatment Either With Ciclosporin or Prednisolone. Completed NCT00919542 Phase 2 Ciclosporin;prednisolone
27 A Pilot Double Blind Controlled Study Randomizing Patients Whose ENL is Not Controlled With Standard Prednisolone, and Comparing a Group Treated With Ciclosporin to a Group Treated With Additional Steroid Only. Completed NCT00919776 Phase 2 prednisolone;ciclosporin
28 Treatment of Idiopathic Pulmonary Fibrosis With Thalidomide Completed NCT00162760 Phase 2 Thalidomide
29 A Phase II Study of Peg-Interferon Alpha-2B (Peg-Intron(TM)) and Thalidomide in Adults With Recurrent High-Grade Gliomas Completed NCT00047879 Phase 2 Thalidomide
30 An Open-Label Study to Evaluate the Efficacy and Safety of TMC207 in Subjects With Multibacillary Leprosy Recruiting NCT03384641 Phase 2 Bedaquiline 200 mg
31 A Single Center, Open Label Pilot Study to Evaluate the Safety and Efficacy of CC-11050 in Nepalese Patients With Erythema Nodosum Leprosum Recruiting NCT03807362 Phase 2 CC-11050
32 Phase 2 Study of Clofazimine for the Treatment of Pulmonary Mycobacterium Avium Disease Recruiting NCT02968212 Phase 2 Clofazimine
33 A Phase 1b / 2a, Double-Blind, Randomized, Placebo-Controlled, Antigen Dose-Escalation Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of LEP-F1 + GLA-SE in Adult Participants in Areas Endemic for Leprosy Not yet recruiting NCT03947437 Phase 1, Phase 2
34 Open-Label Study of Thalidomide for Chronic Prostatitis/Chronic Pelvic Pain Terminated NCT00301405 Phase 2 Thalidomide
35 A Phase II, Open-Label, Single Center Pilot Study to Determine the Safety and Efficacy of THALOMID (Thalidomide) in Patients With Chronic Pancreatitis. Terminated NCT00469703 Phase 2 Thalidomide
36 A Phase 2A, Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety, Tolerability, Pharmacokinetics and Efficacy of Clofazimine (CFZ) in Cryptosporidiosis Terminated NCT03341767 Phase 2 Clofazimine;Placebo
37 The Effects of Virgin Coconut Oil Supplementation on Oxidative Stress and Treatment Response Among Hansen's Disease Patients on Multi-Drug Therapy: A Pilot Study Withdrawn NCT01885611 Phase 1, Phase 2
38 Proposal Evaluation and Intervention Through Prevention of Disability in Leprosy Patients Completed NCT01006759 Phase 1
39 Phase I Study to Evaluate New Leprosy Skin Test Antigens: MLSA-LAM and MLCwA Completed NCT01920750 Phase 1
40 A Phase 1, Open Label, Antigen Dose-Escalation Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of LEP-F1 + GLA-SE in Healthy Adult Subjects Completed NCT03302897 Phase 1
41 Pharmacokinetics and Distribution of Dapsone (DDS) in Leucocytes After Single-dose and Multiple-dose Administration in Healthy Subjects Genotyped for CYP2C9 and NAT2 and in Patients With Autoimmune Bullous Dermatoses Completed NCT02493283 Phase 1 Dapsone single dose;Dapsone multiple dose
42 A Phase I Study of the Safety and Immunogenicity of BCG (Bacille Calmette-Guerin) Vaccine Delivered Intradermally by a Needle Injection in Healthy Volunteers Who Have Previously Received BCG. Completed NCT00654316 Phase 1
43 Pharmacokinetics of Standard First and Second Line Anti-TB Drugs in the Lung and Lesions of Subjects Elected for Resection Surgery Completed NCT00816426 Phase 1 Rifampicin;Isoniazid;Pyrazinamide;Kanamycin;Moxifloxacin
44 A Phase I Study Evaluating the Safety and Immunogenicity of a New TB Vaccine, MVA85A, in Healthy Volunteers Who Are Infected With HIV Completed NCT00395720 Phase 1
45 A Phase I Study Evaluating the Safety and Immunogenicity of a New TB Vaccine, MVA85A, in Healthy Volunteers Who Are Latently Infected With Mycobacterium Tuberculosis. Completed NCT00456183 Phase 1
46 Montelukast as an Alternative or Supplementary Treatment in ENL Reaction in Leprosy Unknown status NCT00406861 montelukast in treatment of ENL reaction
47 Evaluation of Low Level Laser Therapy Effects in Peripheral Nerves Patient Affected With Leprosy : Randomized Controlled Trial Unknown status NCT03072004
48 Molecular Epidemiology of Leprosy - Philippines Completed NCT00315809
49 Molecular Epidemiology of Leprosy in Colombia Completed NCT00138437
50 Clinic-Epidemiological Evaluation of Ulcers in Leprosy Patients and the Use of Low Level Laser Therapy: a Randomized Clinical Trial Completed NCT00860717

Search NIH Clinical Center for Leprosy 2

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Thalidomide

Genetic Tests for Leprosy 2

Genetic tests related to Leprosy 2:

# Genetic test Affiliating Genes
1 Leprosy 2 29

Anatomical Context for Leprosy 2

MalaCards organs/tissues related to Leprosy 2:

40
Testes, Skin, Prostate, Bone, Lung, Breast, T Cells

Publications for Leprosy 2

Articles related to Leprosy 2:

(show all 44)
# Title Authors PMID Year
1
Linkage disequilibrium pattern and age-at-diagnosis are critical for replicating genetic associations across ethnic groups in leprosy. 56
23052943 2013
2
Association study of major risk single nucleotide polymorphisms in the common regulatory region of PARK2 and PACRG genes with leprosy in an Indian population. 56
16391553 2006
3
Susceptibility to leprosy is associated with PARK2 and PACRG. 56
14737177 2004
4
Chromosome 6q25 is linked to susceptibility to leprosy in a Vietnamese population. 56
12577057 2003
5
A major susceptibility locus for leprosy in India maps to chromosome 10p13. 56
11279529 2001
6
Genomic control for association studies. 56
11315092 1999
7
Study of S100 Immunostaining in Demonstrating Neural Granulomas in Paucibacillary Leprosy. 61
29937557 2018
8
Expression of CD64 on Circulating Neutrophils Favoring Systemic Inflammatory Status in Erythema Nodosum Leprosum. 61
27556927 2016
9
Neuropathy in elderly: lessons learnt from nerve biopsy. 61
25362502 2015
10
Delusional infestation: a clinical profile. 61
23466108 2013
11
Patterns of migration and risks associated with leprosy among migrants in Maranhão, Brazil. 61
24040433 2013
12
[The current challenge of imported leprosy in Spain: a study of 7 cases]. 61
21334586 2011
13
[Epidemiological profile of leprosy in a Brazilian municipality between 2000 and 2006]. 61
20305971 2010
14
Leprosy. 61
19454067 2007
15
[Late-occurring cutaneous vasculitis after successful treatment of diffuse lepromatous leprosy: Lucio's phenomenon]. 61
17506277 2007
16
Increased prevalence of human T cell lymphotropic virus type 1 in patients attending a Brazilian dermatology clinic. 61
17622792 2007
17
Study of patients presenting with symptoms of peripheral neuropathy and thickened greater auricular nerve. 61
16340253 2003
18
Male-female (sex) differences in leprosy patients in south eastern Nigeria: females present late for diagnosis and treatment and have higher rates of deformity. 61
12449892 2002
19
Spectrum of dermatopathologic lesions associated with HIV/AIDS in India. 61
12785169 2002
20
Ocular manifestations of leprosy in a noninstitutionalized community in the United States. 61
8185519 1994
21
Denatured muscle grafts for nerve repair in an experimental model of nerve damage in leprosy. 2. Recovery of peripheral peptide-containing nerves assessed by quantitative immunohistochemical study. 61
7514642 1994
22
Intracardiac autonomic ganglion cells in leprosy and dilated cardiomyopathy. 61
8365740 1993
23
[Cutaneous neoplasms during leprosy: 2 case reports]. 61
1293912 1992
24
A study of morbidity pattern among prostitutes attending a municipal clinic in Pune. 61
2789264 1989
25
[Study on prevention of leprosy. 2. Chemo-prophylaxis trial for leprosy household contact children]. 61
3842969 1985
26
Leprosy. XII. T-cell subsets in lepromatous leprosy. 61
6983504 1982
27
Phagocytosis in leprosy. 2. Production of superoxide by circulating blood leukocytes from lepromatous patients. 61
215566 1978
28
Persistence of Australia antigen in leprosy--a frustrating puzzle in immunology. 61
651319 1978
29
The role of protein malnutrition in the pathogenesis of ulcerative "Lazarine" leprosy. 61
824211 1976
30
The histopathology of lepromatous leprosy in the nose. 61
1099180 1975
31
Acid mucopolysaccharide metabolism in leprosy. 2. Subcellular localization of hyaluronic acid and beta-glucuronidase in leprous infiltrates suggestive of a host-Mycobacterium leprae metabolic relationship. 61
4282081 1974
32
Experimental murine leprosy. 2. Further evidence for varying susceptibility of outbred mice and evaluation of the response of 5 inbred mouse strains to infection with Mycobacterium lepraemurium. 61
4604462 1974
33
Immunologic studies on leprosy. 2. Antigenic studies of Mycobacterium leprae. 61
4131110 1973
34
The control and management of leprosy. 2. 61
4496656 1973
35
Lipids in leprosy. 2. Histochemistry of lipids in human leprosy. 61
4102020 1970
36
Leprosy. 2. 61
5434944 1970
37
Nerves in the arm in leprosy. 2. Pathology, pathogenesis and clinical correlations. 61
4098603 1970
38
[Consideration and discussion of the pathogenesis of leprosy, with special reference to the influence of specific histological changes in the reticuloendothelial system on the progress of and recovery from leprosy. 2]. 61
5686369 1968
39
Studies on sulfone resistance in leprosy. 2. Treatment with a riminophenazine derivative (B.663). 61
6006070 1966
40
The facial nerve in leprosy. 2. Pathology, pathogenesis, electromyography and clinical correlations. 61
5950064 1966
41
Epidemiology of disability in leprosy. 2. Factors associated with low disability. 61
5950068 1966
42
Chemotherapeutic trials in leprosy. 2. Comparative trial of dapsone plus ditophal (Etisul) and dapsone alone in the treatment of lepromatous leprosy. 61
5322767 1965
43
[Relation between host resistance and disease type in mouse leprosy. 2. Influence of hyaluronidase on the onset of mouse leprosy]. 61
13751963 1961
44
Classification of leprosy, 2. The value of fat staining in classification. 61
13720258 1960

Variations for Leprosy 2

ClinVar genetic disease variations for Leprosy 2:

6 ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 PRKN NM_004562.3(PRKN):c.823C>T (p.Arg275Trp)SNV Pathogenic 7050 rs34424986 6:162206852-162206852 6:161785820-161785820

Expression for Leprosy 2

Search GEO for disease gene expression data for Leprosy 2.

Pathways for Leprosy 2

Pathways related to Leprosy 2 according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.59 VIP NPY
2 11.46 VIP PRKN NPY CALCA
3 11.32 VIP CALCA
4 10.49 NPY CALCA

GO Terms for Leprosy 2

Cellular components related to Leprosy 2 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell GO:0005623 9.13 PRKN NPY CALCA
2 neuron projection GO:0043005 8.8 VIP PRKN CALCA

Biological processes related to Leprosy 2 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor signaling pathway GO:0007186 9.58 VIP NPY CALCA
2 cellular protein metabolic process GO:0044267 9.43 PRKN CALCA
3 adenylate cyclase-activating G protein-coupled receptor signaling pathway GO:0007189 9.37 VIP CALCA
4 neuropeptide signaling pathway GO:0007218 9.32 NPY CALCA
5 positive regulation of protein catabolic process GO:0045732 9.26 VIP PRKN
6 regulation of blood pressure GO:0008217 9.16 NPY CALCA
7 feeding behavior GO:0007631 8.96 NPY CALCA
8 positive regulation of blood vessel diameter GO:0097755 8.62 VIP CALCA

Molecular functions related to Leprosy 2 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor binding GO:0001664 9.16 PRKN NPY
2 neuropeptide hormone activity GO:0005184 8.96 VIP NPY
3 hormone activity GO:0005179 8.8 VIP NPY CALCA

Sources for Leprosy 2

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....